| Literature DB >> 19601724 |
Alan Boobis1, Jean-Baptiste Watelet, Rhys Whomsley, Margherita Strolin Benedetti, Pascal Demoly, Keith Tipton.
Abstract
Drugs for allergy are often taken in combination with other drugs, either to treat allergy or other conditions. In common with many pharmaceuticals, most such drugs are subject to metabolism by P450 enzymes and to transmembrane transport. This gives rise to considerable potential for drug-drug interactions, to which must be added consideration of drug-diet interactions. The potential for metabolism-based drug interactions is increasingly being taken into account during drug development, using a variety of in silico and in vitro approaches. Prediction of transporter-based interactions is not as advanced. The clinical importance of a drug interaction will depend upon a number of factors, and it is important to address concerns quantitatively, taking into account the therapeutic index of the compound.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19601724 DOI: 10.1080/10837450902891550
Source DB: PubMed Journal: Drug Metab Rev ISSN: 0360-2532 Impact factor: 4.518